State of Alaska Department of Revenue Has $2.40 Million Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

State of Alaska Department of Revenue reduced its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 21.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 22,696 shares of the medical equipment provider’s stock after selling 6,280 shares during the quarter. State of Alaska Department of Revenue’s holdings in Zimmer Biomet were worth $2,397,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of ZBH. Dunhill Financial LLC lifted its holdings in shares of Zimmer Biomet by 1,090.0% during the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 218 shares in the last quarter. Ashton Thomas Securities LLC bought a new position in shares of Zimmer Biomet during the 3rd quarter valued at about $28,000. Brooklyn Investment Group bought a new position in shares of Zimmer Biomet during the 3rd quarter valued at about $35,000. R Squared Ltd bought a new stake in Zimmer Biomet in the 4th quarter valued at approximately $63,000. Finally, Mather Group LLC. lifted its stake in Zimmer Biomet by 100.9% in the 4th quarter. Mather Group LLC. now owns 661 shares of the medical equipment provider’s stock valued at $70,000 after acquiring an additional 332 shares in the last quarter. Institutional investors own 88.89% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the company. Oppenheimer cut their target price on Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 15th. Raymond James dropped their price objective on Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating on the stock in a research note on Friday. Wells Fargo & Company upped their price objective on Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 31st. Royal Bank of Canada dropped their price objective on Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating on the stock in a research note on Friday. Finally, Stifel Nicolaus upped their price objective on Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a research note on Thursday, January 23rd. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $124.15.

Zimmer Biomet Stock Performance

Shares of NYSE ZBH opened at $100.40 on Tuesday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.70. The stock’s fifty day moving average price is $107.34 and its two-hundred day moving average price is $108.07. Zimmer Biomet Holdings, Inc. has a one year low of $99.67 and a one year high of $133.90. The firm has a market cap of $19.99 billion, a price-to-earnings ratio of 22.56, a P/E/G ratio of 1.83 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, beating analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period last year, the business posted $2.20 EPS. On average, equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.25 EPS for the current year.

Zimmer Biomet Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, January 31st. Stockholders of record on Monday, December 30th were given a dividend of $0.24 per share. The ex-dividend date was Monday, December 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.96%. Zimmer Biomet’s payout ratio is 21.57%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.